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 ABSTRACT 
TITLE  
Association between GRK 5 polymorphism and poorly controlled asthma 
BACKGROUND 
Asthma is a chronic inflammation of the airways which are characterized with chest 
tightedness, wheezing, cough and dyspnoea. Despite the presence of effective asthma 
treatments and evidence-based management guidelines specializing in asthma management, 
several patients have bronchial asthma that's inadequately controlled. Several reasons are 
quoted for this poor management like patient non-compliance to treatment, poor inhalation 
technique, lack of response to medications, presence of co-morbid diseases, environmental 
exposure of hazards and genetic influence. Various genes are been researched for identifying 
the genetic factor. One of such unexplored genes is GRK 5 gene. This gene controls the 
kinase and turns off the receptor which results in decreased effect on administration of beta 
agonism.  
AIM 
To find out if GRK5 polymorphism has higher proportion of occurrence in poorly controlled 
bronchial asthmatic patients.  
OBJECTIVE 
1. To study the genetic association (GRK5-Leu41 polymorphism) and control (i.e. therapeutic 
response) in bronchial asthma. 
2. To study the other risk factors associated with poorly controlled asthma. 
 
METHODS 
This was a cross sectional study with 160 patients. After getting informed consent from the 
patients they were divided into two groups (Well and Poor control) based on a self 
administered questionnaire – Asthma control test. Blood was obtained from these study 
participants and their genetic analysis was performed.  
RESULTS 
The prevalence of this polymorphism was found to be 14% in our population. But its 
association with poor control of asthma was not found to be statistically significant 
(p=0.822).Risk factors like known allergic history to dust, smoking history, climatic 
variation, history of GERD, regularity of treatment were all found to have statistical 
significance for poor control of asthma. In our study risk factors like progressing age, female 
sex, environmental hazard exposure, and exposure to pets were not statistically significant for 
poor controlled asthma. 
CONCLUSION  
The current study did not demonstrate a significant association between GRK5-Leu41 
polymorphism and poor control of asthma. 
Key words: Asthma, poor control, GRK 5 polymorphism 
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INTRODUCTION 
The NAEPP National asthma program defines asthma as, chronic 
inflammatory disease of the respiratory system involving several cells 
and its components. In vulnerable people, inflammation causes perennial 
events of coughing, chest tightness, dyspnoea, and wheezing. The 
episodes are sometimes related to airflow disturbance that is reversible by 
treatment or reverses spontaneously. Additionally inflammation ends up 
in a rise in bronchial hypersensitivity to a range of factors.  
Studies done in numerous countries shows, the prevalence of 
bronchial allergic reaction as 15-30 %
1
& incidence about 3.5-20 % of the 
people in all countries
2
. The documented increase in asthma prevalence 
over the last twenty five years is probably as a result of differences in the 
environment & life style as; modification in genetic makeup will take 
quite many generations to occur
3
. Worldwide, asthma cases are 
increasing at a rate of fifty per cent each decade, and in line with WHO 
(World Health Organization), by the year 2020, asthma, beside COPD 
(chronic obstructive pulmonary disease) can become the third leading 
reason behind death. A calculable three hundred million individuals 
within the world have asthma and there may be an extra one hundred 
million persons with asthma by 2025
4
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An epidemiologic multicentre study on the prevalence of asthma in 
Indian adults employing a uniform, valid and standardized methodology 
concluded a prevalence of 1.69-3.47 per cent
5
 with increasing age, 
females, family history of respiratory illness, previous history of atopic 
allergy, lower socio-economic status and urban residence were 
considerably related to asthma
5
. In Delhi in urban center, parental 
smoking, paracetamol intake, exposure to cat, traffic pollution were found 
to be considerably related to current wheezing
6
 whereas in youngsters 
aged 4-15 years in Chandigarh, a 7 % prevalence was observed
8
. India 
accounts for a 3rd of the world’s asthma patients
7
. 
Globally, the cost related to respiratory illness exceeds those of TB 
and HIV/AIDS combined
9
. The economic value of asthma is extensive 
both in direct (hospital visits and price of pharmaceuticals) and indirect 
medical prices (sickness absenteeism and premature death). Developed 
countries expect to pay 1-2% of their health budget on Asthma
4
.Thus the 
sickness burden is a lot of on the morbidity, mortality and conjointly on 
the economic status of the patient thus there's a necessity for higher 
management of the sickness status. 
Despite the presence of effective asthma treatments and evidence-
based management guidelines specializing in asthma management, 
several patients have bronchial asthma that's inadequately controlled. 
3 
 
Several reasons are quoted for this poor management like patient 
non-compliance to treatment, poor inhalation technique
10
, presence of co-
morbid diseases
11
, triggers
12
 like respiratory infections, specifically 
infectious agent
13
, indoor allergens
14
, environmental risky exposures
15
, 
and lack of response to medications
16
. In addition, this data is 
supplemented in consideration with genetic modifiers of environmental 
exposures on expression of asthma. Various genetic alterations, SNP 
(single nucleotide polymorphism) are known within the factors affecting 
asthma and its effective management. E.g. ADRB2 gene, I L 17, TNF 
alpha ,ADAM 33, DPP10 , GRPA, etc
17
. 
One among such polymorphism that has not been effectively 
explored is GRK5 (G protein coupled receptor kinase 5).This study is to 
seek out if there's an association between GRK 5 polymorphism and poor 
control of asthma. 
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AIM 
 
To find out if GRK5 polymorphism has higher proportion of 
occurrence in poorly controlled bronchial asthmatic patients.  
 
OBJECTIVE 
1. To study the genetic association (GRK5-Leu41 polymorphism) and 
control (i.e. therapeutic response) in bronchial asthma. 
2. To study the other risk factors associated with poorly controlled 
asthma. 
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REVIEW OF LITERATURE 
DEFINITION OF ASTHMA 
The word “asthma” is derived from a Greek word meaning 
“panting” or “gasping for breath “.Asthma has been known to mankind 
since ancient times. Asthma in the ancient times was referred as a group 
of disorders that eventually manifested as periods of breathlessness often 
accompanied by a “wheeze”.  
The concepts of pathophysiology of this disease have changed 
from one school of thought to another. In 19
th
 century Henry Hyde 
Salter
18
 thought that both neural and vascular mechanisms were involved 
in development of asthma. He stated that “The inflammation or 
congestion of mucous surface appears to be the stimulus that, through the 
nerves of the air tubes, excites the muscular wall to contract”. Sir 
William Osler thought psychogenic stimuli to be an important cause of 
exacerbation
19
. “All authors agree that there was, in a majority of cases of 
bronchial asthma, a strong neurotic element”, This was written in his 
book “The principles and Practice of Medicine” in 1892. 
In the latter part of 19
th
 century, asthma was largely considered to 
be a psychoneurosis. However research done later tilted towards the 
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etiology toward the environmental agents. Pollen was demonstrated to be 
the cause of hay asthma by Charles Blackle
20
. Similarly the 
demonstration of smooth muscle antigenic sensitizations in animals
21
 and 
the discovery of sensitizing proteins
22
 in plants strengthened the role of 
environmental factors in chronic disease. Rackemann
23
 classified asthma 
as extrinsic and intrinsic depending on the presence or absence of 
recognizable environmental triggers. 
  The CIBA guest symposium
24
 was held in 1958 to arrive at 
common consensus over definitions, classifications and terminology of 
various respiratory disorders; “Asthma refers to a condition in subjects 
with widespread narrowing of bronchial airways which changes in 
severity over short periods of time either spontaneously or under 
treatment and is not due to cardiovascular disease”
24
. Approximately 25 
years after CIBA symposium, the concept of generalized obstructive lung 
disease (GOLD) was introduced to accommodate both reversible and 
irreversible obstruction
25
. Asthma was defined in functional terms; 
however, the threshold of reversibility was not ascertained and this posed 
a diagnostic difficulty. 
Around the same time there was another hypothesis originated 
from Netherlands, which considered reversible airflow obstruction of 
asthma and the largely irreversible airflow obstruction of smokers as the 
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two aspects of the same basic process. This hypothesis did not get 
acceptance in the United Kingdom and North America. 
In 1990, in view of the high morbidity and mortality due to asthma 
in Britain, BTS also released guidelines for the asthma management
26
. In 
these guidelines, asthma is described as “Asthma is a common and 
chronic inflammatory condition of the airways whose cause is not 
completely understood. As a result of inflammation the airways are 
hyperresponsive and they narrow easily in response to a wide range of 
stimuli. This may result in coughing, wheezing, chest tightness and 
shortness of breath; these symptoms are often worse at night. Narrowing 
of the airway is usually reversible, but in some patients with chronic 
asthma the inflammation may lead to irreversible obstruction of 
airflow”
26
. 
However it took a century to reach a consensus regarding 
important components of the disease when in 1991, the National Heart 
Lung and Blood Institute formulated an expert panel group
27
 which as a 
guide to describe asthma an identify treatment direction; put forth a 
working definition of asthma: “Asthma is a chronic inflammatory 
disorder of the airways in which many cells and cellular elements play a 
role: In particular, mast cells, eosinophils, T lymphocytes, macrophages, 
neutrophils and epithelial cells. In susceptible individuals, this 
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inflammation causes recurrent episodes of wheeze, breathlessness, chest 
tightness and coughing, particularly at night or in the early morning. 
These episodes are usually associated with widespread but variable 
airflow obstruction that is often reversible either spontaneously or with 
treatment .The inflammation also causes an associated increase in the 
existing bronchial hyperresponsiveness to a variety of stimuli. 
Reversibility of airflow limitation may be incomplete in some patients 
with asthma.”
27, 28 
This definition was slightly modified in the 2007 Expert panel 
report 3
29
 and was further modified in 2009  and the current definition as 
per the Global Initiative for Asthma (GINA) guidelines
30
 is “Asthma is a 
chronic inflammatory disorder of the airways in which many cellular 
events play a role .This chronic inflammation is associated with airway 
hyperresponsiveness that leads to recurrent episodes of wheezing, 
breathlessness chest tightness and coughing ,particularly at night or 
early in the morning. These episodes are usually associated with airflow 
obstruction within the lung that is often reversible either spontaneously 
or with treatment.” 
Over the past two centuries, defining asthma has been a herculean 
task owing to the lack of knowledge of its exact etiopathogenesis. 
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Although a universally acceptable definition of asthma has emerged, it is 
subject to further modifications based on future research. 
PATHOPHYSIOLOGY 
• The major asthma attack of respiratory disease embrace a variable 
degree of flow obstruction accompanied with edema of the airway, 
bronchoconstriction, increased cartilaginous tube secretion, airway 
inflammation and bronchial hyper responsiveness.  
• Allergens that are inhaled results in an early-phase hypersensitivity 
with activation of  IgE antibodies  which is specific to allergen resulting 
in  stimulation of mast cells & macrophages within the airway releasing 
unhealthy mediators like eicosanoids  and histamines that provoke airway 
smooth muscular contraction, vasodilatation, secretion of mucous 
secretion,  and  plasma exudation within the airways. Reduced mucosal 
clearance is because of outflow of protein which ends up in an 
exceedingly stiffened, dropsical, engorged airway lumen and narrowing 
of the same. 
• The late-phase inflammatory reaction happens six to nine hours 
when substance aggravates and indulges in accomplishment and 
stimulation of basophils, lymphocytes (T), eosinophils, macrophages and 
neutrophils. 
10 
 
• Unleashing of inflammatory mediators like leukotrienes, granule 
proteins, cytokines occurs when eosinophil migrates  to the airways  
• Activation of T-lymphocyte results in cytokines release from TH2 
cells that causes allergic inflammation (IL-4, IL-5, and IL-13). Also TH1 
cells manufacture IL-2 and IF-γ that are important for defense 
mechanisms in cell. Asthmatic inflammation could be due to imbalance 
of this TH1 & TH2 cells. 
• Degranulation of mast cells in reaction  to allergens leads to release 
of mediators like  histamine; leucocyte, and neutrophil factors; 
Leukotriene C4, D4, and E4; PGs; and Platelet Activating  Factor. Sleek 
muscle contraction is caused by histamine and also plays role in mucosal 
wall thickening and secretion. 
• Macrophages in alveoli unleash variety of acute phase reactants, as 
well as Platelet Activating Factor and LT’s. Inflammation is further 
influenced by chemotactic factors from eosinophil & neutrophil. 
• Bronchial hyper responsiveness & inflammation is caused by 
various mediators influenced by neutrophils like: PG’s, TX, LT, and 
Platelet Activating Factor. 
• The 5-LOX pathway is answerable for formation of cysteinyl LT’s. 
LT’s C4, D4, and E4 are present throughout process of inflammation 
11 
 
within lung & turn out spasm, mucous secretion, microvascular 
permeableness, and airway edema.  
• Bronchial animal tissue cells participate in inflammation by 
cathartic eicosanoids, peptidases, matrix proteins, cytokines, and nitric 
oxide. Epithelial shedding leads to heightened airway responsiveness, 
altered permeableness of the airway mucous membrane, depletion of 
epithelial-derived relaxant factors, and loss of enzymes liable for 
degrading inflammatory neuropeptides. 
• The exudative inflammatory method and shedding of animal tissue 
cells into the airway lumen impair mucociliary transport. The gland size 
in bronchus increases & so goblet cell increase in number. Expectorated 
mucous secretion of patients with asthma tends to possess high viscosity. 
• The airway is supplied by sympathetic, parasympathetic, and nor 
adrenergic system. The conventional tone of ASM is maintained by 
efferent vagal activity, and bronchial constriction is mediate by 
stimulation of vagus within tiny bronchi. Airway smooth muscle contains 
non-innervated β2-adrenergic receptors that produce bronchodilatation. 
The nonadrenergic, noncholinergic system within the trachea and bronchi 
could amplify inflammation in respiratory disease by releasing nitric 
oxide
31
. 
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Rise in numbers of mast cells in ASM are specific for bronchial 
asthma. Symptoms in bronchial asthma are attributable to ASM 
contraction, and so bronchodilators are needed as symptomatic relief 
drugs. The physiological hallmark of bronchial asthma is airway hyper 
responsiveness. Whether or not ASM is per se altered in bronchial asthma 
isn't confirmed. However augmented ability of ASM could influence the 
current bronchial hyper responsiveness. Inflammation additionally is also 
orchestrated by nerve fiber that controls TH2 cells which regulate 
inflammation by eosinophils & immunoglobulin production by B 
lymphocytes. Bronchial epithelial tissue has a crucial part by discharge of 
number of inflammatory mediators &thru releasing growth factors to 
correct the injury caused by inflammation. This inflammation in 
bronchial asthma is mediated by discharge of many mediators
32
. Cytokine 
protein networks, together with chemokines and growth factors, play vital 
roles in orchestrating the inflammation method 
33
. 
Asthma mainly characterized by a mode of inflammation mostly 
caused by immune gamma globulin (IgE)-dependent mechanisms. 
Genetic factors plays a crucial influence whether or not atopic allergy 
develops and a number of other genes are been identified
34
. Several 
genetic factors of bronchial asthma are also common to many allergic 
diseases
35
. In addition, environmental factors seem to be additional vital 
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in determinative whether or not an atopic patient results in bronchial 
asthma, though factors related to genetics could impart an effect on how 
severely illness is present and increase in  inflammatory process. 
Mast cells have an important role in causing bronchial asthma 
symptoms, while macrophages, TH2cells & eosinophils are mainly 
concerned with inflammation that causes AHR. There is high fact that the 
cells of bronchi, together with epithelial cells of bronchus and ASM cells 
form a crucial means of mediators of inflammation. Several mediators of 
inflammation are important for bronchial asthma, together with lipid 
mediators & peptide mediators, cytokines, growth factors and 
chemokines. They play important role in specific accomplishment of 
inflammatory mediators in circulation, while cytokines mediate chronic 
type of inflammation. This chronicity may be the reason for 
morphological changes in airways, with subepithelial pathology, ASM 
hyperplasia, growth & mucous secretion. Pro-inflammatory transcription 
factors, like NF-kB and GATA-3 has main role in forming expression of 
genes related to inflammation. 
Many internal mechanisms are there that balance the inflammation 
in asthma and a few proofs these could also be reduced in asthma. Owing 
to complexness in bronchial asthma medication which focuses on a cell / 
intermediator is less likely supply vital clinical advantage;  
14 
 
Beta2-Agonists don't seem to be solely the foremost acting 
bronchodilators; however beta agonists additionally inhibit plasma leak & 
mast cells, while corticosteroids inhibit many inflammatory process &  
also  production of chemokines and cytokines. 
RISK FACTORS 
Asthma may be an advanced cluster of conditions, and efforts are 
created to outline phenotypes/endotypes based on age of onset, duration, 
severity, presence of hypersensitivity reaction and alternative factors. 
There are several modifiable and non modifiable risk factors for the 
patients and this will influence the episodes of exacerbation, hospital 
admission, frequency of medications etc. Factors embrace better-known 
allergens, environmental pollutants, smoking history, co morbidities and 
a lot of more.  
Environmental triggers influence asthma at totally different times 
in life. And even the better-known risk factors could modify over time for 
a personal .This may ensue to sensitization following exposure or 
tolerance to the substance.  
Short term studies of risk issue could counsel there's a rise in 
probability of asthma however constant risk factors is also related to a 
decreased risk once followed up for a longer time or the other way 
15 
 
around. 
A wheezing trigger is something that irritates airways and causes 
symptoms. Triggers could embrace animal hair, exercise, food, 
medicines, spore or farming dusts, climatical changes and tobacco smoke. 
OCCUPATION 
Between two hundred and three hundred agents are encountered at 
work that is reportable to cause asthma attack through respiratory 
sensitization.
35, 36, 37
. Exposure to environmental tobacco smoke has been 
a predominant hazard  and a few proof suggests that such exposure in 
adulthood will increase the danger of asthma attack
38
.Workplace 
exposure to environmental tobacco smoke has been coupled with asthma 
attack .
39, 40, 41 
 
A study done in guinea pigs where the animals were gone through few 
respiratory pollutants like  
• Endotoxin, 
• Cotton Dirt, 
• β-glucan and 
• Tannin 
Endotoxin recapitulated neutrophil adherence, tachypnea, and 
decreased airway conductance with exposure of cotton dirt, though toxin 
16 
 
didn't influence contraction of ASM which was isolated
42
.A study in 
human volunteers who were healthy didn’t show a dose-response changes 
in FEV1 in relation with cotton dust
43
. 
A novel animal model was prepared for workers in cotton textile; 
toxins were used to assess difference in early with late responses. 
Significant changes in bronchial hyper-reactivity with 5 day exposure 
was seen, in comparison with redoubled bronchial airways resistance 
when 8 wks exposure. Which is often in line with the finding like cotton 
dirt could cause reversible then fastened air flow hindrance over time. 
Curiously, rising period in toxin exposure is related to risen pneumonic 
inflammation. 
Also together with this the growth of dendritic cells & decrease in 
macrophages necessary for  resolution of  inflammation was  found out, 
which can be  a mechanism of chronic hyper reactive airway found in 
textile workers
44
. 
AIR POLLUTION 
 The mortality after first of 20
th
 century was smogginess in United 
States of America & European Union, without ambiguity proved the link 
between pollution and airway illness. Pollutants which lead to increased 
risk of recurrence in wheezing patients included 
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• Sulphur dioxide (SO2) 
• Smoke  
• Nitrogen dioxide (NO2) 
• Ozone (O3)  
• Hydrocarbon and  
• Diesel  
Dangers exposed by pollutants are assessed by seasonal outdoor 
concentrations & conjointly exposure of wheezing subjects individually 
and relation with different co-variances. 
 Proof of pollution implies that it should stimulate exacerbations in 
patients with asthma attack; however there is no proof to recommend like 
pollution starts asthma attack among people with antecedently good 
lungs
45
. Employing different type  of epidemiologic methods, exposure 
and outdoor pollutants was connected to exacerbations symptoms by ER 
visits
46,47
, hospital admissions
48,49
, mortality
50,51
, enhanced URT and LRT 
symptoms
52,53
 and reduced lung function
54,55
. 
Studies done in controlled chamber conjointly allowed finding the 
airway response aggravated by inspiration of mobile dusts that provide 
amount of the propensity to cause exacerbation. Few studies done in 
populations of young and old asthmatics showed different response to 
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completely different pollutants, however ensuring general redoubled 
status in wheezing in comparison with non – asthmatic subjects
56
. 
FOOD  
 There are many case-reports demonstrating asthma attack are often 
triggered by foods, & is reduced by change in diet. Symptoms attributable 
to Immunoglobulin E-mediated hypersensitivity may occur if the food is 
not habitually eaten, leading to hypersensitivity reaction, which can be in 
the course of exacerbated asthma attack. Food habitually eaten may 
present as chronic asthma attack typically related to atopic eczema. In 
pediatric age group it present as asthma with classical sign some time 
with exacerbation of symptom
57
. 
 Adults with above normal weight  relation with disease understand 
that food  plays important role in control of disease. A study of  hundred 
thirty five adults asthmatics attending an hypersensitivity reaction clinic, 
seventy three had symptoms due to food, and sixty one managed to 
change their diet so improve their management of disease
58
. 
In a study Seventeen percent of adults. Who had food intolerance 
also was atopic
59
. Most reason behind food evoked asthma attack are 
discovered in infancy and are then typically associated with egg, flour, 
peanuts and cow’s milk hypersensitivity. In spite of influence of foods in 
19 
 
acute attack, a study with placebo done with double blind in controlled 
setting is standard for identification response to foods. Such studies have 
shown that <1% of patients could have proof of acute attack due to food 
60
. Hence general prevalence is around four to six percent for kids, less 
than one percent in adult patients. 
GASTROESOPHAGEAL REFLUX 
GERD is also an initiator of asthma attack; anti reflux medical care 
is also useful in selective patients with poorly controlled asthma as well 
as repeated exacerbation. Many researchers have related esophageal 
reflux with asthma attack which proves GERD is also a risk factor
61
. 
Mechanism is mostly due to  exaggerated vagal stimulation due to acid 
stirred up receptors in esophagus, micro aspiration of acid within airway 
and enhanced ventilation when acid is exposed are the foremost possible 
causes. Regular anti reflux medical care is probably going to boost 
prognosis in twenty to seventy percent of adult patients
62, 63
. A study 
review done enclosed three ninety six cases reported that 9 of the entire 
twelve studies there was vital improvement in a minimum of one 
outcome or overall symptoms. However results weren't standard in 
studies
64
. 
 
20 
 
NOISE 
Noise pollution also influences changes in respiratory epithelium. 
Animals  exposed to recordings of textile area noise almost daily/40 
hrs/wk caused vital changes in bronchial ciliated cells at one month that 
stayed throughout study period; this could cause improper mucociliary 
clearance & cough
65
. 
SMOKING 
Previous studies have disclosed that cigarette smoking will induce 
airway inflammation and increase airway responsiveness
66, 67, 68
 and it’s 
related to an asthma attack phenotype
69, 70
. Passive tobacco smoke 
exposure is related with onset of disease attack in early childhood
71
, 
augmented emergency room visits for kids with asthma
72
, and 
exaggerated respiratory symptoms among the overall population
73
. 
Though active and passive cigarette smoking is well-recognized risk 
factors for asthma, solely a little of people manifest asthma attack. Some 
have speculated that people could vary in genetic status to cigarette 
smoke
74, 75
 however gene–smoking interactions haven't been examined in 
asthma or chronic obstructive lung disease. Increased airway mucosal 
permeability and nonspecific airway responsiveness have additionally 
been discovered in cigarette smokers with lung respiratory organ 
function
76, 77
. 
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Exposure to tobacco smoke either through active smoking or by 
passive smoke cause and/or exacerbate an acute attack or sickness 
symptoms. For individuals exposed to passive smoke at their work the 
danger of developing adult onset asthma attack is alleged to be double 
that of these who aren't exposed to passive smoke. For individuals 
exposed to passive smoke at home the danger of developing asthma 
attack is 5 fold
78, 79
. The 2001 Health Survey for England found that being 
exposed to passive smoke for six or additional hours during a week have 
considerably multiplied risk of wheezing. 
A study conducted in 2006 identified that regular cigarette smoking 
by adolescents will increase the danger of asthma in teenagers with no 
lifetime history of asthma or wheezing. Teenagers who preserved often 
were fourfold additional seemingly to develop asthma attack over 
succeeding eight years than nonsmokers
80
.The airways of an individual 
with asthma attack are terribly sensitive to triggers. Tobacco smoke has 
been found to be a significant asthma attack trigger and it can even have 
an effect on the severity of an attack. 
It is typically assumed and expected that individuals with asthma 
attack avoid smoking. However, a study in 2006 conducted in United 
Kingdom of Great Britain and Northern Ireland found that 24% of adults 
with asthma attack do have the habit of smoking. A Californian study in 
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2001 additionally found no distinction in prevalence of smokers with 
asthma attack (20.2%) and people without (18.8%).
81
 
People with bronchial asthma who smoked and still smoke have 
worse symptoms and knowledge a lot of fast decline in pneumonic 
function than people who have asthma however don't smoke. Those 
individuals with asthma attack and who smoke are additional liable to 
chest infections as a result of the body isn't ready to get eliminate the 
smoke from lungs properly. Another study found that compared those 
with nonsmoking asthmatics, smokers had additional respiratory 
symptoms and had options almost like those found within the early stages 
of chronic obstructive pulmonary disease (COPD)
 82
. 
People with asthma who smoke are doubtless to experience higher 
rates of hospitalization than those with asthma that don't smoke.
83
 
Together with diminished lung function, tobacco decreases the 
effectiveness of medication. 
Quitting smoking has been shown to enhance the respiratory organ 
function of individuals with asthma attack. One study showed improved 
lung performance and a fall in mucus neutrophil (phlegm) levels once 
individuals quit smoking for six weeks compared to those that continuing 
to smoke
84
. Stopping smoking will improve the health of individuals with 
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bronchial asthma and thus each effort ought to be created to encourage 
those with asthma who smoke to prevent smoking.
82
 
Research revealed at the end of 2003 concluded that passive smoke 
will cause asthma in adults
85
 .This was supported in 2005 by the Royal 
college of Physicians. Analysis by the IARC shows the strongest 
causative impact of passive smoke exposure is chronic respiratory 
symptoms in adults. For individuals exposed to passive smoking at their 
locality, risk of developing adult onset bronchial asthma is double that of 
these not exposed. For folks exposed to passive smoking at home, risk of 
developing asthma attack is 5 folds. 
OBESITY 
Asthma & obesity are main issues distressing many people in 
world. It is commonly based on BMI. There are many studies done to 
spot the assorted risk factors and multiple mechanisms involving the 
relation for poor management of asthma attack and fatness. Majority of 
the studies imply that there's relation between obesity & poor 
management of BA; few studies recommend no association
86
 .One review 
article in 2013 by Shannon Nonosad et al. has concluded that asthma 
attack and obesity express a significant relationship with difficult-to-
control phenotype, which has impaired responses to controller drugs. 
Such set of patients are additional seemingly to possess a poor quality of 
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life, a lot of symptoms, exacerbations likewise more emergency 
medications. The augmented risk during this constitution is also as a 
result of alteration in inflammation from changes in levels of leptin, 
adiponectin, there will be high oxidative stress, and  obesity elicited 
changes in volume of lung. 
Another study by Carlos et al. conducted in United States 
population in 1999, concluded that BMI features a sturdy independent 
and positive association with the chance of adult onset asthma. 
Additionally the exacerbations and not only obese people it also 
discovered that, the chance of asthma is increased even in people with 
BMI 22.5 to 24.9
87
.This level is below the quality clinical level of obesity 
definition and thus is unlikely to possess to have to any identification 
bias. And each woman enclosed during this study with weight considered 
being normal or an average was at a rather exaggerated risk. It's 
additionally a vicious cycle as a result of when patients become poorly 
controlled asthmatics their physical and day to day activity is been 
restricted and this successively results in increase in BMI of that patient. 
GPCR & GRK 5 
A wide range of extracellular signals, like  
• Neurotransmitters 
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• Hormones 
• Chemokines 
• Light and 
• Odorants  
are sensed by G protein coupled receptors (GPCRs). Over 1000 
types of this receptor are present. All GPCRs known so far has standard 
structure of seven membrane-spanning helices and which mediates 
signals from extracellular to intracellular by stimulating G proteins
88
. 
GPCRs span around plasma membrane like bundle of 7 α helices
89
. 
Humans express over 800 GPCRs which forms 3
rd
 biggest group of genes 
in humans, with roughly half of these GPCRs dedicated to sensory 
perception (smell, taste, and vision). The remaining receptors regulate an 
impressive number of physiological functions including nerve activity, 
tension of smooth muscle, metabolism, rate and force of cardiac 
contraction, and the secretion of most glands in the body. Included among 
the ligands for GPCRs are 
• Eicosanoids, 
• Peptide hormones,  
• Neurotransmitters - Acetyl choline,  
• Lipid signaling molecules,  
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• Opioids, 
• Biogenic amines - Nor epinephrine,  
• Amino acids – GABA,  
• Other peptide and protein ligands.  
GPCRs are important regulators of nerve activity in the CNS and are the 
receptors for the neurotransmitters of the peripheral autonomic nervous 
system. For example, ACh released by the parasympathetic nervous 
system regulates the functions of glands and smooth muscle through its 
action on muscarinic receptors. NE released by the sympathetic nervous 
system interacts with adrenergic receptors to regulate cardiac function 
and the tone of vascular smooth muscle. Due to their number, 
physiological importance, GPCRs are targets for many drugs; almost half 
of non-antibiotic drugs act thro these receptors 
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ACTIVATION  
When an agonist binds to a GPCR, there is a conformational 
change in the receptor that is transmitted from the ligand-binding pocket 
to the second and third intracellular loops of the receptor which couple to 
the G protein heterotrimer. This conformational change causes α subunit 
to exchange its bound GDP for GTP. Binding of GTP activates the α 
subunit and causes it to release both the βγ dimer and the receptor, and 
both the GTP-bound α subunit and the βγ heterodimer become active 
signaling molecules
90
. The interaction of the agonist-bound GPCR with 
the G protein is transient; following activation of one G protein, the 
receptor is freed to interact with other G proteins. Depending on the 
nature of the α subunit, the active, GTP-bound form binds to and 
regulates effectors such as adenylyl cyclase (via Gsα) or phospholipase C 
(via Gqα). The βγ subunit can regulate many effectors including ion 
channels and enzymes such as PI3-K. The G protein remains dynamic 
until GTP bound to alpha subunit is hydrolyzed to GDP. The alpha 
subunit has a slow intrinsic rate of GTP hydrolysis that is modulated by a 
family of proteins termed regulators of G protein signaling (RGSs). The 
RGS proteins greatly accelerate the hydrolysis of GTP and are potentially 
attractive drug targets
91
. Once the GDP attached to alpha subunit 
hydrolyzed to GDP, the βγ subunit and receptor recombine to form the 
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inactive receptor-G protein heterotrimer basal complex that can be 
reactivated by another ligand-binding event. 
DESENSITISATION 
Receptors in addition to regulation of biochemical process & 
physiological function also subject themselves to many homeostatic and 
regulatory controls. These controls include  
• Covalent modification 
• Regulation of synthesis  
• Association with other regulatory proteins  
• Degradation of receptor and  
• Relocalization within cell.  
Similar regulation of transducer and effector protein occurs; through 
modulatory inputs from other receptors, and receptors always has the 
feedback regulation by their own signaling outputs. 
Desensitization may be due to temporary inaccessibility of receptor 
to agonist and also from other  receptors which are being synthesized and 
available on cell surface. Phosphorylation of G Protein Coupled receptors 
by specific G Protein Coupled receptor kinases (GRKs) has a main role in 
stimulating rapid desensitization. Phosphorylation of agonist-occupied 
GPCRs facilitates binding of cytosolic proteins like arrestins to receptor, 
30 
 
ends in uncoupling of G protein
92
. These β-arrestins stimulates proteins 
like PDE4, which limit cAMP signaling which promote receptor 
sequestration  from the membrane known as internalization, thereby, 
forming a scaffold that prevents further signaling steps. 
CLINICAL FEATURES 
Bronchial asthma, affects airways as an inflammatory disorder with 
chronic inflammation. There is no single pathognomic histological 
feature, there are common findings like cell infiltration with T- 
lymphocytes, neutrophils & eosinophils, epithelial cell dysplasia, 
typically with blocking of tiny bronchi with mucus; deposition of 
collagen below membrane; smooth muscle hypertrophy of cartilaginous 
tube; dropsical bronchi; activation of mast cell; and epithelial tissue 
removal in bronchi. Such inflammation is basis of chronicity and causes 
AHR & limitation of air flow
93
. 
Patients who are sensitive to allergens when exposed will result in 
inflammation of airway, AHR and symptoms. This may form as 
immediate response like wheeze or in four to six hours as late wheezing 
response. 
Common allergens are  
• Cockroaches 
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• House dust mites 
• Cat dander and  
• Seasonal pollens.  
Considerably reducing such things decrease pathognomic findings and 
symptoms. Signs & symptoms differ wide according to patient. Bronchial 
asthma is presented by asthmatics that are episodic in nature, dyspnoea, 
tightness of chest & cough. Increased mucus secretion is commonly seen.  
Some asthmatics have irregular, occasional attacks whereas some patients 
have regular symptoms. 
Signs of attack could occur itself or could also influence and increased by 
alternative factors as mentioned before. Signs are often severe at night; 
bronchiolar tone variation based on circadian rhythm and cartilaginous 
tube response is high between 3- 4 am, during which bronchial 
contraction is at its peak. 
General findings raise the likelihood of acute attack. Mucosal edema, 
exaggerated secretions, and polyps in nose are usually present in allergic 
attack of asthma patients. Atopic dermatitis, eczema, or alternative 
presentation of dermatological disorders due to allergy may be present. 
Chest examination could also be seen without any signs between acute 
attacks in mild asthma. During very severe asthma attack, flow is also 
restricted so only diagnostic sign on auscultation will be widely decreased 
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breath sounds with increased time in expiration. Signs like hunching of 
shoulders &increased use in accessory muscles signify a increased labour 
of breathing. 
LABORATORY FINDINGS 
Arterial blood gas measurements is also traditional during a mild 
asthma attack exacerbation, however alkalosis and a rise within the 
alveolar-arterial oxygen distinction is prevalent. When there is very 
severe exacerbation, hypoxia develops & PaCo2 comes back to normal. 
Hence mixture of accumulated acidosis & PaCo2 could denote an 
imminent failure of respiration & also want for other means of ventilation 
like mechanical. 
 PULMONARY FUNCTION TEST  
Physicians can determine obstruction in air flow on clinical 
examination; however there is need to assess severity and whether disease 
is reversible or irreversible. Analysis of disease ought to thus include 
spirometry (forced expiratory volume in one second [FEV1], forced vital 
capacity, (FEV1/FVC) both baseline & after starting short acting drugs. 
Also such investigation helps to confirm level of flow obstruction, also its 
reversibility. Airflow hindrance is shown by decreased FEV1/FVC 
magnitude relation. Main result of obstruction of air flow shown through 
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rise of more than or equal to 12%, two hundred ml in FEV1 or more than 
or equal to 15 %   and 200 ml in Forced vital capacity[FVC] when using 
bronchodilator of minimal action. An affirmative drug action powerfully 
proves designation of attack however scarcity of positive response within 
the PFT doesn't confirm prognosis during a clinical study about 
bronchodilator. High flow hindrance ends up with more air trappings, a 
rise in respiratory volume and subsequent decrease in restrictive 
ventilatory deficiency like restrictive lung disease. 
Bronchial stimulation testing using methacholine or histamine in 
inhaled form is also helpful once you suspected as asthmatic, however 
PFT is not a diagnostic. Bronchial stimulation isn't counseled when FEV1 
is a smaller amount than Sixty five% of the expected. 
An affirmative test using methacholine is outlined as ≥ twenty 
percent decrease within Forced expiratory volume1 at reaction to strength 
of eight mg/ml or low. Challenge test using exercise is also helpful in 
asthmatics having exercise stimulated bronchospasm.  
PEFR meters are hand-held instruments planned as watching tools used 
personally. Monitoring of PEFR will prove variability in peak flow; 
assess severity of asthma attack, and supply patient & practitioner with 
readings to decide basic treatment. Also different opinions on whether or 
not using PEFR has effect on prognosis; however PEFR is suggested as it 
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may assist to make sure final diagnosis, to enhance management for 
patients with poor flow in airways, and to know environmental, 
occupational reasons for signs and symptoms. Foreseen measurement of 
PEF differ depending upon gender, age etc 
Comparing with standard values is of less value than comparing 
patient’s baseline values .PEF varies diurnally, low on morning and high 
at mid day. Peak Expiratory flow ought to be seen by early morning 
before giving drug and within noon after drug. A twenty percent diurnal 
change or day change indicates poorly controlled disease. Peak expiratory 
flow rate below two hundred ml/min shows very severe air flow 
obstruction. 
OTHER INVESTIGATIONS 
Regular X-ray of chest in cases with regular attack is typically 
traditional else has solely increased inflation. Alternative signs could 
embrace cartilaginous tube wall edema and decreased lung shadows. X 
ray chest is needed once respiratory illness, another any other disease 
simulating asthma or consequence of disease like pneumothorax or any 
other is suspected. 
Intradermal skin test to know sensitivity to allergens in 
environment will determine type I allergic reaction in cases with regular 
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attack, could have the gain of treatment focused at allergy sensitivity. 
Investigation for GERD ought to be thought in BA patients having 
persistent signs & symptoms and recurrence. Noninvasive investigation 
for airway inflammation includes measuring symptom evoked mucus, or 
fractional NO concentration in expired breath (FeNO), gives positive 
outlook on diagnosis & management methods. Managing corticosteroid 
dosage to reduce mucus symptom seems to scale back the recurrence of 
exacerbations in comparison to typical  management, however 
information are differing concerning the importance of FeNO on asthma  
outcomes. 
DIFFERENTIAL DIAGNOSIS 
It’s important to think about situations that simulate respiratory disease in 
cases with atypical signs & symptoms or decreased response to medical 
aid. Such disease usually make up in any of 4 types: 
• Psychiatrical disorders. 
• Upper airway disorders 
• General vasculitides, and  
• Lower airway disorders 
Upper respiratory tract diseases that simulate BA are  
• Vocal cord palsy 
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• Inhalation injury 
• Foreign body aspiration 
• Tracheal narrowing 
• Vocal cord dysfunction syndrome 
• Laryngotracheal masses, 
• Tracheomalacia 
• Airway swelling.  
Lower respiratory diseases are 
• Chronic bronchitis 
• Non-asthmatic COPD  
• Emphysema 
• Cystic fibrosis 
• Allergic bronchopulmonary fungal infection 
• Bronchiectasis 
• Eosinophilic pneumonia 
• Bronchiolitis obliterans. 
Systemic  
• Churg-Strauss syndrome.  
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Psychiatric causes like  
• Conversion disorders,  
• Vocal fold dysfunction 
• Episodic laryngeal dyskinesis.  
• Emotional laryngeal asthmatic  
• Münchausen syndrome 
CURRENT TREATMENT  
The goals of bronchial asthma medical aids is mainly attenuate 
symptoms of disturbing the regular activity (also exercise), also to reduce 
recurrent  attacks, and  cut back or reduce  necessity for acute visits to 
hospitals, and take care of normal pulmonary function. 
 Such aim ought to be seen whereas giving drug treatment with low side 
effects and fulfilling the expectation of cases and their relations. 
Recommendation by NAEPP 3 points regular treatment with anti-
inflammatory property like corticosteroids in inhaled route as main point 
of management of severe bronchial asthma. 
The management includes chronic controller medication and short 
term reliever medications. Long run medications embrace anti-
inflammatory medication like corticosteroids, long acting 
bronchodilators, anti cholinergic, phophodiesterase inhibitors, leukotriene 
modifiers, desensitisation 
vaccination. 
 Short acting relieve
corticosteroids and antimic
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DRUGS REDUCING INFLAMMATION 
Steroids are the foremost active and systematically acting drug 
presently given. These drugs cut back acute & chronic inflammation, 
leading to less respiratory disease signs, increase in flow of air, attenuate 
airway hyperresponsiveness, and decreased asthma recurrences. Such 
drugs additionally enhance the effect of beta agonists. 
Corticosteroids in inhalation route are most well-liked, initial drugs 
for cases with chronic respiratory disease. Such drugs fasten the recovery 
of airflow hindrance & reduce relapse. Patients with regular symptoms or 
recurrences who are not on inhaled steroids ought to be started with the 
same. Foremost choice of drug and required dosing depends upon status 
of patient & response. 
Dose depends on type of drug and device used, most patients 
required management given two times daily for good management of 
disease. Some patients it’s fine with daily dosing. Systemic side effects 
might happen with large dose  inhaled steroid hormone treatment. Local 
side effects includes irritation and fungal infection which can be 
overcome by washing mouth after MDI use and this also prevents 
systemic absorption of the drug. 
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Systemic steroids are effective primary treatment in cases with 
severe BA and for patients with recurrences, those do not respond to 
treatment quickly to inhalation therapy. In such patients there is need of 
chronic suppression of signs, many efforts have done to reduce the 
dosage to less amount required to manage the symptoms Day after day 
treatment is most well-liked. Coinciding management along with calcium 
& Vit D should be started to forestall osteoporosis due to corticosteroid in 
chronic administration. Bisphosphonates might provide further protection 
for those patients. Speedy discontinuance of systemic route of steroids 
once in chronic use might cause adrenal insufficiency. 
Delay in administering corticosteroids might lead to late benefits 
due to these drugs. So, oral steroids should be there for quick treatment at 
home for several patients with wide range of respiratory disease. 
Borderline dose of systemic steroids for such is not known. Patient 
prednisolone “burst” treatment is 0.5–1 mg/kg per kg per day as single or 
2 divided doses for three to ten days. 
Severe manifestation need admission in hospital usually need one 
mg per kg of prednisolone or methylprednisone every sixth hour for forty 
eight hours or when FEV1 comes back to fifty percent of baseline value. 
Dosage is then given up to sixty mg per day until PEFR is seventy 
percent of expected value, there is no advantage when dose is increased 
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in severe manifestations. Also intravenous route will be better for patients 
who are critically ill to avoid first pass metabolism.  
BETA- ADRENERGIC AGONISTS 
Beta agonists both long acting and short acting are available. Long 
acting drugs offer bronchodilatation for up to twelve hours, when one 
dose is administered. Commonly used long acting agonists include 
salmeterol and formoterol. They are available as dry powder and are 
administered using delivery devices. These drugs are indicated for control 
of asthma symptoms, night symptoms and for bronchospasm induced by 
exercise in a long run. These drugs on addition to ICS they produce the 
management comparable to the one which is achieved on doubling the 
dose of ICS. These long acting drugs are not used as monotherapy, as 
they lack anti inflammatory property. Additionally in two large trials 
when they are given as monotherapy it lead to risk of severe and fatal 
asthma attacks. This risk could have been even due to genetic variations 
in the beta adrenergic receptors or some other individual variation and 
hence this remains as a locality of controversy. The effectiveness of 
LABA and ICS has led to selling of them in combination medication that 
delivers each agent at the same time. Formoterol and budesonide have 
shown effectiveness even as both maintenance and rescue medication 
owing to the short time of onset for formoterol. 
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Though exacerbation short acting drug are the most effective, it 
includes albuterol, levoalbuterol, terbutaline, pirbuterol etc. It is the drug 
of choice and most patients ought to take one among these agents during 
acute symptoms. There are no big studies stating one drug is better over 
other. These drugs relax the airways by relaxing the smooth muscle and 
by increasing the airflow thereby relieving the broncho constriction and 
reducing the symptoms. To prevent exercise induced bronchospasm they 
are administered before exercise. Selective beta 2 agents have less cardiac 
receptor stimulation compared to non selective group of beta agonist. 
Inhaled β-adrenergic medical aid is as effective as oral or parenteral 
therapy in airway smooth muscle and improving acute respiratory disease 
and offers the benefits of speedy onset of action (< five minutes) with 
fewer systemic side effects. Repetitive administration produces 
progressive bronchodilatation. One or 2 inhalations of a short-acting 
inhaled β2-agonist from MDI are sometimes enough for mild to moderate 
symptoms. Severe exacerbations often need higher doses: 6–12 puffs 
each 30–60 minutes of bronchodilator by MDI with an inhalation 
chamber or 2.5 mg by nebulizer offer equivalent bronchodilation. 
Administration by nebulization doesn't provide more effective 
delivery than MDIs however will offer higher doses. There is a difference 
in dosing between the metered dose inhaler and nebulizer. Without the 
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note on dose nebulizer are advised for patients who are not able to co 
ordinate between drug delivery and inhalation.  
ANTI-CHOLINERGICS 
The long-acting anti-cholinergic tiotropium has been studied as 
add-on medical aid for patients who have either a bronchodilator response 
or a positive methacholine challenge that's not adequately controlled with 
low-dose ICS. With 14 weeks of treatment, adding tiotropium resulted in 
enhancements in PEF, FEV1, and symptom control; the enhancements 
were larger than those achieved by doubling the dose of the ICS for an 
equivalent amount of time. The addition of tiotropium wasn't inferior to 
the addition of salmeterol. The short treatment amount doesn't allow a 
determination of whether or not long β2-agonists are similar to tiotropium 
in reducing asthma exacerbations and whether or not it's a good and safe 
alternative to long β2-agonists for the long-term management of asthma. 
Anti-cholinergic agents reverse vagus mediation of bronchospasm 
however allergen mediated or exercise evoked spasm is not reversed. 
They’ll diminish mucous gland secretion present in respiratory disease. 
Ipratropium bromide, a quaternary by-product of atropine freed from 
atropine like side effects, is a smaller amount effective than β2-agonists 
for relief of acute spasm, however it's the inhaled drug of choice for 
patients with intolerance to β2-agonists and with bronchospasm as a 
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result of b-blocker medications. Ipratropium bromide reduces the rate of 
hospital admissions once additional to inhaled short-acting β2-agonists in 
patients with moderate to severe asthma exacerbations. 
PHOSPHODIESTERASE INHIBITORS 
Theophylline provides mild bronchodilation in wheezy patients. 
Theophylline also mediates anti-inflammation property, 
immunomodulation properties, augments mucociliary drainage, and 
strengthens diaphragmatic contraction. Extended release theophylline 
preparations are useful in controlling night symptoms and as additional 
therapy in patients with severe type of asthma attack whose symptoms are 
inadequately controlled by ICS. Once added to inhaled corticosteroids, 
theophylline could permit equivalent control at lower corticosteroid 
doses. Theophylline serum concentrations have to be compelled to be 
monitored closely as a result of very small therapeutic index, variations in 
drug metabolism, and factors affecting absorption and metabolism. 
At therapeutic doses the adverse effects includes sleep disorder, 
provocation of indigestion and GERD symptoms, and urinary flow 
obstruction with benign prostatic hypertrophy. Toxic dose side effects 
embrace nausea, vomiting, increased heart rate, headache, epilepsy, 
hyperglycaemia, and electrolyte imbalance. New drugs are in clinical 
trials for selective inhibition of PDE-4. 
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Methylxanthines don't seem to be recommended for medical care 
during acute attacks. Aminophylline as a single drug therapy is found to 
be inferior to beta agonism for acute attack. And if patients who are on 
theophylline has an attack and acute doses of theophylline are planned to 
be used as management, then their serum concentrations are to be 
measured before administration to prevent toxicity. 
LEUKOTRIENE MODIFIERS 
Leukotrienes are the mediators of airway obstruction through 
smooth muscle contraction, augmenting vascular permeability and 
mucous secretion, accompanied with activation of inflammatory cells. 
Drugs modifying leukotriene includes 5-lipoxygenase inhibitors, Zileuton 
which decreases the production of leukotrienes, and drugs antagonizing 
the leukotriene receptor includes montelukast and zafirleukast. In 
randomised controlled trials, these agents showed improvements in PFT 
and decreased the dose of beta agonist therapy when used as rescue 
medication. These are the drug of choice in mild types of asthma, but as a 
monotherapy they are inferior to inhaled corticosteroids. In pragmatic, 
real-life community trials, leukotriene receptor antagonists were 
equivalent in efficaciousness to an inhaled corticosteroid as first-line 
long-term controller medication or to a long-acting β-agonist as add-on 
medical care. Zileuton will cause raise in LFT which is reversible on 
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stoppage of drug and few people with Churg-Strauss syndrome has been 
diagnosed in an exceedingly tiny range of patients on chronic intake of 
montelukast or zafirleukast, though this can be suspected to be an impact 
of corticosteroid withdrawal as against an immediate drug effect. 
DESENSITIZATION 
Immunotherapy for specific allergens is also thought of in hand-
picked asthma patients who have exacerbations of asthma symptoms 
when exposed specifically to the specific allergen and who are not 
responding to the conventional treatments.  
Studies show a reduction in respiratory disease symptoms in 
patients treated with single-allergen immunotherapy. Due to the chance of 
immunotherapy-induced bronchoconstriction, it ought to be administered 
only in a setting wherever such complications are often at once treated. 
OMALIZUMAB 
Omalizumab is an IgE antibody produced by recombinant 
technology and acts by binding to the immunoglobin without mast cell 
activation. Omalizumab has proved to reduce the dose of corticosteroid 
use when administered to patient with moderate to severe type of asthma. 
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VACCINATION 
Patients with respiratory disease ought to receive pneumococcal 
vaccination and annual asthma influenza vaccine. Out of active and 
inactive vaccine, inactive vaccines are related to lesser side effects; 
however use of the live attenuated influenza vaccine intranasally could 
also be related to a rise in asthma exacerbations in young children. 
ANTIMICROBIALS 
Various studies have demonstrated that infection with viruses 
especially with rhinovirus and bacteria’s like mycoplasma or chlamydia 
may lead to acute exacerbation. Hence usages of antibiotics are suggested 
during these exacerbations. Regular usage of antibiotics without 
exacerbation is not recommended, as there are no consistent testimonies 
which claim to improve clinical outcome with antibiotic usage. 
Antibiotics ought to be thought of once who are at high probability for 
respiratory tract infections like fever or evidence of pneumonia and 
sinusitis. 
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TOOL USED 
Various measures for control of asthma 
There are numerous strategies used to evaluate the asthma control. 
It includes ACSS (asthma control scoring system), ACT (asthma control 
test), ACQ (asthma control Questionnaire), ATAQ (Asthma therapy 
assessment questionnaire), AQLQ (Asthma Quality of life questionnaire) 
and many more. 
Among these ACT and ACQ are the foremost often used tests. The 
easy to administer questionnaires include ACT and ATAQ as they're 
symptom based evaluation, whereas ACQ and ACSS include pulmonary 
function test. Additionally limitation of ATAQ is that it doesn’t include 
the presence of day time symptoms. AQLQ is extremely helpful for 
quantification of quality of life in bronchial asthma and response 
treatment than the control. ACT in specific has been found to be helpful 
for primary health care development in developing countries
94
. 
LITERATURE FOR ASTHMA CONTROL TEST 
Accurate assessment of control is a very important a part of asthma 
management. Inadequate assessment of control could be a major issue for 
poor control of asthma
95
. It is not patients alone who overestimate their 
control
96, 97
, clinicians conjointly tend to try to do the same
98,99,100
.Asthma 
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control test (ACT) is  a self-administered tool for assessing patients with 
poor control,  comprising five-item questionnaire with symptoms and 
daily activites are recalled for  4 weeks  , need of rescue medication, and 
self-rating of  asthma control
101
. It has been made known to show a 
relationship with a physician’s ratings of control
102
 .5-point scale (for 
symptoms and activities: 1=all the time to 5= not at all). The scores vary 
from 5 (poor control of asthma) to 25 (complete control of asthma), with 
higher scores reflective greater asthma management. An ACT score >19 
indicates well-controlled asthma. The only limitation of this form is, it's a 
multidimensional construct, but doesn't include objective measures of 
airway caliber. ACT has conjointly been validated to be used by mail
103
 
and by telephone
104
. Be aware of asthma control as the main intension for 
treatment, is the revised guidelines of GINA in 2006 for prompt 
management, supported based on  control instead of on disease 
severity
105
. Same concept is also seen with different national 
guidelines
106, 107
. 
  The modified GINA guideline defines 3 levels of control; ‘Well-
controlled’, ‘partly controlled’ and ‘uncontrolled’. While the GINA 
criteria define a conceptual framework for assessing asthma control, the 
ACT could be a sensible tool enabling clinicians to use the GINA 
recommendations. The ACT is straightforward to use and provides a 
52 
 
consistent, numeric score which will assist in watching symptom control 
over time
102
. Wider use of the ACT and similar instruments ought to 
facilitate assessment of the asthma burden in the community. Better 
assessment of control could lead to improved management, greater 
patient awareness and understanding of their asthma, and ultimately to 
better patient outcomes. 
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METHODOLOGY 
 
STUDY CENTRE: 
The study was done in the Department of Pharmacology, PSG Institute of 
Medical Sciences and Research and the Department of Endocrinology, 
PSG Hospitals, in collaboration with the PSG Centre for Molecular 
Medicine and Therapeutics (CMMT). 
STUDY SUBJECTS: 
 Inpatients and outpatients of Respiratory Medicine and 
Pulmonology department with clinical diagnosis of asthma from February 
2013 to July 2014 
STUDY DESIGN: 
The study was a cross sectional study .After obtaining informed 
consent and fulfilling the inclusion exclusion criteria patients were given 
the self administered questionnaire in their language and divided into well 
controlled and poorly controlled group. Blood sample was  collected from 
all the patients and their genetic analysis was done. 
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Picture 5 :FLOWCHART OF STUDY DESIGN 
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SAMPLE SIZE: 
Sample size of 160 patients were recruited comprising of 80 
patients in each group 
ETHICAL APPROVAL: 
The study protocol was approved by the Institutional Human Ethics 
Committee (IHEC) preceding the start of the study. The details and the 
purpose of the study protocol were explained to each participant 
individually and their doubts were clarified before obtaining informed 
consent. The informed consents forms provided to the participants were 
either in English or in Tamil. The participants, who gave written 
informed consent, and came under the inclusion criteria, were enrolled for 
the study. A copy of the consent form is attached in the annexure.  
TOOL USED 
Asthma control test -a validated self administered questionnaire used to 
assess control of asthma in patients. 
 Score >19 – well controlled       Score < 19 – poorly controlled 
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INCLUSION CRITERIA 
• All patients diagnosed to have asthma according to the accepted 
guidelines and on treatment atleast for past one year.  
• Ability and willingness to provide informed consent  
• Age >12 years 
EXCLUSION CRITERIA  
Nil 
GENETIC ANALYSIS: 
Steps involved in genotype analysis were; 
• DNA extraction 
• PCR to amplify GRK 5 gene 
• RFLP using BsrI restriction enzyme 
• PAG electrophoresis of the digested product 
DNA EXTRACTION  
CELL LYSIS 
 Blood (300µl) + I volume of cell lysis buffer (buffer c) + 3 volume 
of water, mix up by inverting the samples. 
 Incubate the samples on the ice (refrigerator ) for 10 minutes 
 Centrifuge the samples at 4° C for 20 minutes at 4000 rpm 
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 Discard the supernatant and leave the cuvettes open for a while. 
 And add 150µl of ice cold buffer in every sample. 
 Again add 480 µl of autoclaved H2O and close the cuvette. 
 Disturb the pellet by using vortexer or by mixing with pipette. 
 Centrifuge the sample at 4°C for 30 minutes at 4000 rpm. 
 Yet again, discard the supernatant. 
NUCLEIC ACID LYSIS  
 As soon as supernatant discarded, add 720µl of nucleic acid lysis 
buffer , along with add 12-15µl of RNase A 
 Vortex the samples and incubate it for 10 -15 minutes at 37°C. 
 Add 30µl of 10% SDS and 35 µl of proteinase K 
 Incubate the sample in water bath at 55°celcius for two-three hours. 
 Add phenol: chloroform (1:1), vortex the samples and centrifuge 
for ten minutes at15800rpm. 
 Extract the supernatant of the samples (aqueous layer) and transfer 
it to another tube. 
 Same volume of chloroform is added, vortex the samples and 
centrifugefor ten minutes at 15800 rpm . 
 Transfer the supernatant or the  aqueous layer  to another tube, add 
0.1× volume of 3M of NaaC (90) at ph of 6.0 
 Again, add 2× volume of 100% ethanol. 
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 Store the samples overnight at -20°Celcius. (10 mins-70*) 
 DNA can be found at the pellet after centrifuging at 15800 rpm for 
20 minutes. 
 Completely wash the DNA wit h 70 % of ethanol dry it and re 
suspend the DNA pellet in 50µl TE buffer. 
AGAROSE GEL ELECTROPHORESIS  
 
Reagents required: 
1. TAE buffer 50 X stock: 
           24.2g Tris base 
           5.7ml Glacial Acetic acid 
           10ml 0.5M EDTA pH 8.0 
           Dissolve in 100 ml Distilled water 
2. TAE buffer 1X Tank buffer: 
Dilute the 50X TAE buffer to 1X by adding water. For eg 
(10ml 50X TAE + 490ml Water) it becomes 1X TAE. Use it for 
electrophoresis tank to run the gel. 
3. DNA loading dye 
4. Ethidium bromide. 
5. Agarose powder. 
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Gel preparation: 
• Take fresh 50ml 1X TAE buffer (based on gel template size) in a 
conical flask and add 0.4g agarose (0.8% gel), heat the solution 
well. 
• Before that seal the Gel template with cello tape and keep the well 
template ready. 
• Then, add 2ul ETBR solution with heated 5oml solution mix well 
and pour it in sealed gel template and leave it for a while to 
become a gel. 
Electrophoresis: 
• Load the 1X TAE buffer in tank (~600ml required) and keep the 
gel plate inside the tank. 
• Then take 2ul DNA loading dye and 8ul DNA (isolated) mix well 
and load it in wells carefully. 
• Set the volt at 75V and run it for 30-45 mins. Then analyze the 
DNA bands using gel document machine. 
•  Quantification of the extracted genomic DNA was done using 
Nanodrop quantification after 0.8% agarose gel electrophoresis. 
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GRK 5 RFLP PCR  
REQUIREMENTS: 
1. PRIMERS (SIGMA) 
S. NO 
 
PRIMERS 
 
2
0
 STOCK  
CON 
FINAL CON  
 
1 Forward primer   
GRK5 bsrF 
1µM 50 nM 
2 Reverse primer    
GRK5 bsrR 
1µM 50 nM 
2.  DNTPs (Himedia)  
S. 
NO 
DNTPS 
STOCK 
 
1
0
STOCK 
CON 
2
0
 
STOCK 
CON 
FINAL 
CON 
1 100Mm 
each DNTPS 
10mM each 
DNTPS 
2.5mM 
each DNTPS 
100µM  
each DNTPS 
     
3.  Taq DNA polymerase (colour Taq Genei) (Stock 1 Unit/ µl, Final 
con 0.1 unit) 
4. Taq Buffer A (Genei) (Stock 15mM Mgcl2, Final con 1.5mM 
Mgcl2) 
5. DNA Sample Optimised concentration: 0.03µg/ 20µL 
6. Milliq water 
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PCR REACTION MIX 
S. NO COMPONENTS VOLUME FINAL 
CONCENTRATION 
1 Forward primers 1 GRK5 bsrF  - 
1 µM      
1 µL 50 nM 
2 Reverse primers 1 GRK5 bsrR   - 
1 µM                       
1 µL 50 nM 
3 Taq Buffer A                          2 µL 1.5mM Mgcl2 
 
4 DNTPs 0.8 µL 100µM  each 
DNTPS 
5 Taq enzyme                              0.2 µL 0.01 unit 
 
6 DNA sample (0.03µg) - 0.03µg/ 20µL 
7 Milli Q UPTO 20 µL  
 
 
PCR PROGRAME 
1. Initial denaturation -  94⁰C  for 10 min 
2. Denaturation  -  94⁰C  for 30 sec       40 CYCLES 
3. Annealing                    -  60⁰C  for 30 sec               
4. Extension                       -  72⁰C  for 1 min 
5. Final extension              -  72⁰C  for 5 min 
6. Then held at 4⁰C   
 PCR amplification confirmed on 2% agarose gel 
 PCR product size is 224 bp 
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RESTRICTION DIGESTION  
REQUIREMENTS 
1. BstUI/ Bsh 1236 I (Fermentas 10units/ µL) 
2. 10 x Buffer R 
3. PCR product  
Optimized Concentration 
For wild Homozygous        - 2 µg 
For Mutant Homozygous  - 2 µg 
For Heterozygous         - 3 µg 
4. 37oC & 65oC  incubator  
REACTION MIX FOR RFLP 
S. NO COMPONENTS VOLUME 
1 BsrI Enzyme               1 µl 
2 10X Buffer                                5 µl 
3 DNA concentration      1 µg 
4 Total Rxn volume 50 µl 
 Mix gently & spin down for few seconds 
 Incubate at 65⁰C  for 15-40 mins 
 Restriction digestion product is inactivated at 80⁰C  for 20 min 
before gel electrophoresis 
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POLYACRYLAMIDE GEL ELECTROPHORESIS 
 The DNA Fragments separated using  15 % Polyacrylamide gel 
electrophoresis 
 Polyacylamide gel prepared from the following reaction mix 
 
15% GEL 
 
5mL 10mL 15mL 20mL 25mL 30mL 40mL 50mL 
Water 
 
1.2 2.3 3.5 4.6 5.7 6.9 9.2 11.4 
A:B (30:0.8) 
 
2.5 5 7.5 10 12.5 15 20 25 
1.5M Tris pH 8.8 
 
1.3 2.5 3.8 5 6.3 7.5 10 12.5 
10% SDS 
 
0.05 0.1 0.15 0.2 0.25 0.3 0.4 0.5 
10% APS 
 
0.05 0.1 0.15 0.2 0.25 0.3 0.4 0.5 
TEMED 
 
0.002 0.004 0.006 0.008 0.01 0.012 0.016 0.020 
 
 Polyacylamide gel was run in Amersham electrophoresis system at 
100 V for about 5 hours 
 The gel was then stained with ethydium bromide  
 The stained gel was viewed in a Chemiluminescence gel 
documentation system to identify the DNA fragments 
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RESULTS 
 
Fig 1  : Distribution of Male and Female among asthmatics 
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Fig 2 : Distribution of Male and Female among well controlled and 
poorly controlled asthmatics 
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Fig 21 : Percentage of polymorphic individuals 
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Fig 22 : Distribution of polymorphism among well controlled and 
poorly controlled patients 
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STATISTICS TABLE 
 
 
 
 
 
 
Variable P Value OR CI-Lower CI-Upper 
     
AGE 0.409 1.314 0.687 2.514 
BMI 0.205 1.495 0.801 2.79 
FAMILY HISOTRY 0.035 0.502 0.262 0.958 
REGULAR TREATMENT 0.000 0.206 0.087 0.489 
GERD 0.017 2.17 1.146 4.107 
ACTIVE SMOKING 0.035 2.846 1.043 7.765 
PASSIVE SMOKING 0.197 1.614 0.777 3.353 
ENVIRONMENT 
HAZARDS 0.429 1.259 0.691 2.392 
DUST ALLERGY 0.028 2.27 1.081 4.771 
CLIMATE VARIATION 0.017 2.158 1.143 4.076 
SMOKE ALLERGY 0.028 0.401 0.175 0.919 
FOOD ALLERGY 0.035 0.298 0.092 0.969 
HARSH SMELL 
ALLERGY 0.043 2.333 1.014 5.371 
URTI 0.000 3.265 1.680 6.344 
SINUSITIS 0.000 5.174 2.331 11.482 
HOSPITAL ADMISSION 0.000 8.143 2.675 24.791 
CASUALTY VISTS 0.000 4.636 2.178 9.868 
PETS 0.063 0.495 0.234 1.047 
SNP 0.822 1.107 0.456 2.68 
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DISCUSSION 
This cross sectional study was undertaken to evaluate the 
association of GRK 5 single nucleotide polymorphism (GRK5 SNP) and 
poorly controlled asthma.  
Our central hypothesis was that there would be a positive 
association between the GRK5 SNP and poor control of asthma, because 
of a reported endogenous beta blockade by this SNP
108
. We chose to 
study asthma because of its increasing prevalence every year and even 
with appropriate therapy, more number of people continues to have poor 
control of asthma
109
. 
The total number of patients recruited in the study was 160, and 
there were 37% males and 63% females .Among them, 53 % of males 
and 52 % females were poorly controlled. Previous community based 
studies have shown female sex as a risk factor for developing 
asthma
110
.This was also observed in our study as the male: female ratio 
was 1: 1.7. In spite of this female preponderance in poorly controlled 
asthma group, it was not statistically significant. This has been previously 
noted in a different study by Dursun et al
111
.  
In our study we found that age did not seem to influence control of 
asthma as well. Though Odds Ratio from our results was 1.314 indicating 
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that older the age greater was the chance for developing poorly controlled 
asthma, the confidence interval for this OR stands at 0.69 to 2.5. 
Therefore we could not treat this result as significant. Noteworthy was 
that 65 % of patients were of age group >40 years. 
Though in our study population, a statistically significant 
difference between control of asthma in obese and non–obese subjects 
was not detected (p=0.205) and OR is 1.495 (95 % CI 0.801- 2.790), 
there is said to be an increased association of poor control of asthma with 
increasing BMI in previous studies. Mosen et al. concluded obesity is 
associated with worse asthma outcomes and also increased asthma related 
hospitalizations
112
.The possible mechanism for this association was 
formulated by Shore in 2008, who demonstrated in a mouse model that 
obesity is a state of chronic low grade inflammation with adipose derived 
hormonal influence and sleep disordered breathing which is associated 
with decreased lung volume and tidal volume resulting in airway 
narrowing
113
. 
Curiously, family history of asthma appeared to be negatively 
correlated with poorly controlled asthma yielding a statistical significance 
of p=0.035, and an OR of 0.502 (95 % CI 0.264 to 0.958). Most of prior 
literature on family history of asthma seems to be prevalence studies 
rather than examining association between family history of asthma and 
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its control. From our study, patients with positive family history are 
found to have better control compared to those without a positive family 
history.  This could have been due to increased awareness in the family 
about the disease, its outcome and treatment modalities and the need for 
therapeutic compliance. Thus, the patients in our study with a positive 
family history may have achieved a good control of asthma.  
Our data for compliance of treatment and poor control shows a 
sturdy association (p < 0.001) with OR 0.206 and Confidence interval 
falling between 0.087 and 0.489. This implies that patients with regular 
treatment history are well controlled. This is understandable from the fact 
that in asthma, compliance improves outcome. A recently published 
population based cohort study in Canada showed that people adherent to 
treatment had less exacerbation, less hospitalizations, lower health care 
utilizations and need for less rescue medications
114
. 
On the basis of medications 25 % used inhaled corticosteroids 
maintenance monotherapy, 55% used inhaled corticosteroid and 20% 
used additional anticholinergic medication at the time of study 
recruitment. But there was no significant difference among the patients 
taking only ICS (Inhaled corticosteroids) or ICS + LABA (long acting 
beta agonist) or ICS + LABA + Anticholinergic .This is similar to a 
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Canadian study in which proportion of controlled and uncontrolled 
patients were same irrespective of their medication used
115
. 
It was also found that patients who had history of hospitalizations 
(p<0.001) OR 8.143 (CI 2.7-24.7) and casualty visits (p<0.001) with OR 
4 (CI 2.2 – 9.9) in past one year fell under the poorly controlled arm. This 
is an expected statistical association because these are used as diagnostic 
criteria for poorly controlled asthma. 
Other co morbid conditions like hypertension, diabetes and 
tuberculosis were not found to be significantly associated with control of 
asthma. It is remarkable that none of the patients were treated with beta 
blockers for hypertension among the study participants. This could be 
reflected from fact that beta blockers are currently not the first line of 
drug for hypertension and moreover use of beta blockers are essentially 
avoided by clinician treating patients with asthma. It was also noted that 
common anti hypertensive drugs used were amlodipine and telmisartan, 
and anti diabetic drugs used were glimepride and metformin. 
In our study population about 14% were smokers and 24% had 
history of passive smoking. Passive smoking recipients included co 
workers and those who had husbands who smoke. The features associated 
with smokers and asthma are increased symptoms and disability coupled 
with accelerated decline in FEV1, therapeutically reduced response to 
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corticosteroids and pathological alteration in airways with inflammation 
and increased bronchial secretion
116
. Our results revealed statistically 
significant association between active smoking and poor control but not 
significant for passive smokers. 
Similarly exposure to other environmental pollutants also plays a 
role as risk factor for asthma. Our study participants were mostly patients 
residing near cotton mills, rice mills, working in textile industry and 
exposed to farming dust. Surprisingly the association between control and 
that of these hazards was not statistically significant (p=0.429) with OR 
of 1.25(95% CI 0.690-2.392).This could be due to the fact that patients 
were already on controller medications, though it s detrimental and 
causing progression of airway inflammation in asthma, the patient may 
not manifest the symptoms or acute exacerbation. Similar explanation 
could be also offered for patients who had pets, as they showed no 
statistically significant difference in their asthma control. 
Known allergy or atopy to dust, smoke, seasonal variation, allergic 
to food and harsh smell (which included perfumes, smell during sautéing 
food, paint fumes, onions) were considered. Some of these like dust, 
season and harsh smell showed statistically significant positive 
association for poorly controlled asthma, whereas smoke and food allergy 
did not show significant association. 
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Patients with coexisting GERD showed statistically significant 
correlation (p=0.017) OR of 2.170 (95% CI 1.146-4.107) for poorly 
controlled asthma. Multiple studies have stated this positive association 
between GERD and difficult to treat asthma. Nearly one third asthma 
patients have silent reflux
117
. 
The rationale in support of this is due to the relaxation of the 
gastroesophageal sphincter as a result of bronchodilator therapy, 
flattening of diaphragm due to air trapping, activation of vagal reflex by 
cholinergic pathway and accompanied with microaspiration of stomach 
contents. 
Also history of upper respiratory tract infection and history of 
sinusitis were found to have statistically significant (p <0.001) 
relationship to poorly controlled asthma. This could be due to the grounds 
that these may not be causally related to control in asthma rather the 
result of poor control. 
Beside all these factors, our central hypothesis was to examine if 
there would be a positive association between GRK 5 SNP and poor 
control, because of a demonstrated endogenous beta blockade by the 
SNP. Hence we suspected that if this polymorphism were present in an 
asthmatic individual, he/she may have a decreased activity of the drug 
due to a pre-exisiting beta blockade. 
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Consistent with this functional effect , agonist promoted beta2-AR 
phosphorylation was greater in cells expressing GRK5-Leu41, similar to 
the rate of agonist promoted receptor internalization. So GRK5-Leu 41 
represents a gain of function polymorphism that evokes enhanced loss of 
function of Beta2-AR during persistent agonist exposure, and thus 
contributing to beta agonist variability in asthma treatment. 
This GRK5-Leu 41 variant is approximately 10 fold more common 
in African- Americans
118
. It was found that the prevalence of this 
polymorphism is variable between different populations depending on the 
ethnicity. In some races the SNP was seen in around 2 % of the 
population while in the African Americans it was as high as 40 % 
108
. Our 
study population had 14 % of GRK5-Leu41 variant. 
A prior study has demonstrated a higher prevalence of this SNP 
among African Americans compared to Caucasian
108
. Another study 
showed that African Americans exhibit a poorer control of asthma as well 
as potentially greater adverse effects during chronic treatment when 
compared with Caucasians
118
. Though a prospective study has not yet 
been conducted to demonstrate a link between the SNP and poorer 
control of asthma in this population, the authors of the SMART study 
suggest that among other things, a genetic factor may well be the 
underlying reason for the same. 
96 
 
So we were interested in looking at how GRK5 polymorphism 
affected asthma control among the Indian population. However,  the 
frequency of this variant was equal among those with well controlled and 
poorly controlled asthma. Thus the difference in frequency distribution of 
this polymorphism did not show any statistical significance (p=0.822). 
The reason for such an inference could be due to the small sample 
size of our study .Other plausible explanation could be because of the 
influence of the same SNP on muscarinic receptors resulting in 
bronchodilatation that could be exhibiting a possible functional 
antagonism on the effects of this SNP on beta 2 adrenoreceptors.  
Desensitization of Beta 2 AR’s through GRKs. 
Beta 2 Adrenergic receptor is a GPCR, which on activation by a 
agonist leads to GαS activation which in turn activates adenylcyclase(AC) 
,which hydrolyses adenosine triphosphate(ATP) into cyclic adenosine 
monophosphate (cAMP) . The binding of cAMP to regulatory subunits 
proteins of cAMP (PKA), releases the catalytic subunit of the PKA, and 
activated PKA exerts numerous effects in airway smooth muscle by 
phosphorylating many intracellular targets. 
In addition to the PKA mediated β2AR signaling it is appreciated 
that regulatory protein arrestins can promote β2AR signaling events 
distinct from those of PK
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Picture 9 : Role of polymorphism on GRK5 
 
 
 
 
 
 
 
 
Additionally one study has demonstrated that M2 muscarinic 
receptor mediated opposition of airway smooth muscle relaxation is 
regulated by GRK5 which is important in beta 2 receptor desensitization. 
In addition that study concluded GRK 5 regulates pulmonary response in 
a tissue specific and receptor specific manner 
119
. 
It has further been noted that bronchial relaxation via beta 2 
adrenoceptors has both direct and indirect components. The indirect 
component is through phosphorylation of M3 receptors resulting in 
reduced production of IP3 leading to bronchial relaxation.   
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It is equally possible that the functional antagonism (as discussed 
above) exhibited between M3 and β2 adrenoceptors could well underlie 
the fact that those with SNP were also seen in the well controlled arm.  
Thus there could be variability in responses to these patients with 
GRK5 polymorphism either because enhanced beta blockade causing 
poor control or enhanced M3 mediated relaxation making them symptom 
free and well controlled. 
Chronic use of beta adrenergic agonists is known to lead to 
desensitization of the receptor
88
. This desensitization could by itself result 
in poor control of asthma. Therefore, duration of treatment is a potential 
confounding factor, and this needs to be taken into account while 
interpreting the genetic effects.  
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CONCLUSION 
1. This is the first study in Indian population done to assess the genotype 
phenotype correlation of GRK5 gene polymorphism and poor control of 
asthma 
2. The prevalence of this polymorphism was found to be 14% in our 
population. 
3. The current study did not demonstrate a significant association 
between GRK5-Leu41 polymorphism and poor control of asthma. 
4. Risk factors like known allergic history to dust, smoking history, 
climatic variation, history of GERD, regularity of treatment were all 
found to have statistical significance for poor control of asthma. 
5. In our study risk factors like progressing age, female sex, 
environmental hazard exposure, and exposure to pets were not 
statistically significant for poor controlled asthma. 
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ABBREVATIONS 
 
 
WHO   -  World Health Organization 
 
COPD   -  chronic obstructive pulmonary disease 
 
SNP    -  Single Nucleotide Polymorphism  
 
GRK   - G protein-coupled receptor kinase 
 
GPCR  -  G protein-coupled receptors 
BTS    -  British Thoracic Society  
NHLBI  -  NIH Heart, Lung and Blood Institute 
 
GINA    -  Global Initiative for Asthma  
 
IgE   -  Immunoglubulin E 
 
PG   - prostaglandin 
 
LOX   - Lipoxygenase 
 
ASM    -  Airway smooth muscle 
 
TH 1 & 2   –  T-Helper cells 1&2 
AHR    –  Airway Hyperresponsiveness 
NF-KB  -  nuclear factor – kappa beta 
GATA-3   - Trans-acting T-cell-specific transcription factor 
PEFR -  Peak Expiratory Flow Rate 
BA - Bronchial Asthma 
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I am Dr.R.Keerthana Brattiya carrying out a study on the topic: Association 
between GRK5 polymorphism and poorly controlled asthma 
 
As part of my research project being carried out under the aegis of the 
Department of:  Pharmacology 
 
My research guide is: Prof.S.Ramalingam 
 
The justification for this study is: to identify whether genetic polymorphism 
has effect on the control of asthma as a result in future my study will help them 
identify the appropriate group of drugs for their effective control 
 
The objectives of this study are:  
To study the risk factors associated with poorly controlled asthma  
To study genetic association (GRK5 Leu 41 polymorphism) and control (i.e. the 
therapeutic response) in bronchial asthma. 
 
Sample size: 150 patients 
 
Study participants are: Asthma patients above the age of 18 
 
Location: PSGIMSR, Coimbatore 
 
We request you to kindly cooperate with us in this study. We propose collect 
background information and other relevant details related to this study. We will 
be carrying out:  
 
Initial interview :10 to 15 minutes.  
 
Data collected will be stored for a period of fifteen years. We will / will not use 
the data as part of another study.  
 
Blood sample collection: 2 ml.  
 
No. of times it will be collected: Once 
 
Whether blood sample collection is part of routine procedure or for research 
(study) purpose:  Research purpose  
 
Specify purpose, discomfort likely to be felt and side effects, if any: To do 
genetic analysis and no discomfort or side effects 
 
Whether blood sample collected will be stored after study period:  No, it will be 
destroyed 
 
Whether blood sample collected will be sold: No  
 
Whether blood sample collected will be shared with persons from another 
institution: No 
 
Medication given, if any, duration, side effects, purpose, benefits:  No 
medications 
 
Benefits from this study: To identify whether the patient has the polymorphism 
and that is the cause for his poor control of asthma 
 
Risks involved by participating in this study : No risks 
 
How the results will be used:  the results will be used for further researches 
and publications 
 
If you are uncomfortable in answering any of our questions during the course of 
the interview / biological sample collection, you have the right to withdraw 
from the interview / study at anytime. You have the freedom to withdraw 
from the study at any point of time. Kindly be assured that your refusal to 
participate or withdrawal at any stage, if you so decide, will not result in any 
form of compromise or discrimination in the services offered nor would it 
attract any penalty. You will continue to have access to the regular services 
offered to a patient. You will NOT be paid any remuneration for the time you 
spend with us for this interview / study. The information provided by you will 
be kept in strict confidence. Under no circumstances shall we reveal the identity 
of the respondent or their families to anyone. The information that we collect 
shall be used for approved research purposes only. You will be informed about 
any significant new findings - including adverse events, if any, – whether 
directly related to you or to other participants of this study, developed during 
the course of this research which may relate to your willingness to continue 
participation. 
 
Consent: The above information regarding the study, has been read by me/ read 
to me, and has been explained to me by the investigator/s. Having understood 
the same, I hereby give my consent to them to interview me. I am affixing my 
signature / left thumb impression to indicate my consent and willingness to 
participate in this study (i.e., willingly abide by the project requirements).  
 
Signature / Left thumb impression of the Study Volunteer / Legal 
Representative:  
 
 
 
 
 
 
 
  
 
 
Signature of the Interviewer with date:     
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PSGIMSR 
Case Report Form  
Patient name:      IP/OP no: 
Age/Gender:      Address: 
           
Height:    Weight:                BMI: 
Occupation – (Current &Past): 
 
Any Hazardous exposure in work place: 
Ethnicity (Religion/caste): 
H/o known allergens: 
Personal History:  
Smoking –(cigar/beedi, How many, How long) 
Alcohol- 
Other Sub Abuse- 
H/o exposure to irritants (paint fumes , household sprays) 
Family History 
(H/O, asthma, atopic dermatitis,Eczema, allergic rhinitis) 
Disease related details 
1)Asthma-> Duration of disease 
                    Treatment 
 2) Co morbid conditions & treatment (Drugs like beta blockers, Aspirin) 
HT 
DM 
TB 
Others 
3) No of emergency visits in last year 
4) No of hospitalization in last year 
5) During past 4 weeks have you had 
-Respiratory Infection 
-GERD symptoms 
-Rhino sinusitis 
-Pets 
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இuni0BB0_uni0BC1uni0BA8_uni0BCDதuni0BA4_uni0BC1? 
1. ஒuni0BB0_uni0BC1  நாளிuni0BB2_uni0BCD ஒuni0BB0_uni0BC1 uni0BAE_uni0BC1ைறuni0B95_uni0BCDuni0B95_uni0BC1 ேமuni0BB2_uni0BCD  
2.  ஒuni0BB0_uni0BC1 நாளிuni0BB2_uni0BCD ஒuni0BB0_uni0BC1 uni0BAE_uni0BC1ைற  
3.  ஒuni0BB0_uni0BC1 வாரuni0BA4_uni0BCDதிuni0BB2_uni0BCD  3 uni0BAE_uni0BC1தuni0BB2_uni0BCD 6 uni0BAE_uni0BC1ைற  
4. ஒuni0BB0_uni0BC1 வாரuni0BA4_uni0BCDதிuni0BB2_uni0BCD  1 அuni0BB2_uni0BCDலuni0BA4_uni0BC1 2 uni0BAE_uni0BC1ைற 
5. uni0BAE_uni0BC1uni0BB1_uni0BCDறிuni0BB2_uni0BC1uni0BAE_uni0BCD இuni0BB2_uni0BCDைல  
 
3.   கடuni0BA8_uni0BCDத 4 வாரuni0B99_uni0BCDகளிuni0BA9_uni0BCD ேபாuni0BA4_uni0BC1, எuni0BA4_uni0BCDதைன uni0BAE_uni0BC1ைற 
ஆuni0BB8_uni0BCDuni0BA4_uni0BCDமாவிuni0BA9_uni0BCD  அறிuni0B95_uni0BC1றிகuni0BB3_uni0BCD ஆன uni0BAE_uni0BC1uni0B9A_uni0BCDசிதிணறuni0BB2_uni0BCD இuni0BB0_uni0BC1மuni0BB2_uni0BCD, ெநuni0B9E_uni0BCDuni0B9A_uni0BC1 
இuni0BB1_uni0BC1uni0B95_uni0BCDகuni0BAE_uni0BCD அuni0BB2_uni0BCDலuni0BA4_uni0BC1 வலி , இவuni0BB1_uni0BCDறிuni0BA9_uni0BCD காரணமாக இரuni0BB5_uni0BC1 அuni0BB2_uni0BCDலuni0BA4_uni0BC1 
விuni0B9F_uni0BBFயuni0BB1_uni0BCD   காைலயிuni0BB2_uni0BCD வழuni0B95_uni0BCDகuni0BA4_uni0BCDதிuni0BB1_uni0BCDuni0B95_uni0BC1 மாறாக   ந$uni0B99_uni0BCDகuni0BB3_uni0BCD பuni0B9F_uni0BC1uni0B95_uni0BCDைகயிuni0BB2_uni0BCD 
இuni0BB0_uni0BC1uni0BA8_uni0BCDuni0BA4_uni0BC1 எuni0BB4_uni0BC1uni0BA8_uni0BCDuni0BA4_uni0BC1 ெகாuni0BB3_uni0BCDள ேநuni0B9F_uni0BCDடuni0BA4_uni0BC1  ? 
1. ஒuni0BB0_uni0BC1 வாரuni0BA4_uni0BCDதிuni0BB2_uni0BCD  4 அuni0BB2_uni0BCDலuni0BA4_uni0BC1 அதuni0BB1_uni0BCDuni0B95_uni0BC1 ேமuni0BB1_uni0BCDபuni0B9F_uni0BCDட இரuni0BB5_uni0BC1களிuni0BB2_uni0BCD 
2. ஒuni0BB0_uni0BC1 வாரuni0BA4_uni0BCDதிuni0BB2_uni0BCD 2 அuni0BB2_uni0BCDலuni0BA4_uni0BC1 3 இரuni0BB5_uni0BC1கuni0BB3_uni0BCD 
3. வாரuni0BAE_uni0BCD ஒuni0BB0_uni0BC1 uni0BAE_uni0BC1ைற 
4. ஒuni0BB0_uni0BC1uni0BAE_uni0BC1ைற அuni0BB2_uni0BCDலuni0BA4_uni0BC1 இuni0BB0_uni0BC1uni0BAE_uni0BC1ைற 4 வாரuni0B99_uni0BCDகளிuni0BB2_uni0BCD 
5. uni0BAE_uni0BC1uni0BB1_uni0BCDறிuni0BB2_uni0BC1uni0BAE_uni0BCD  இuni0BB2_uni0BCDைல 
 
4. கடuni0BA8_uni0BCDத 4 வாரuni0B99_uni0BCDகளிuni0BB2_uni0BCD ேபாuni0BA4_uni0BC1, ந$uni0B99_uni0BCDகuni0BB3_uni0BCD உuni0B99_uni0BCDகuni0BB3_uni0BCD மீuni0B9F_uni0BCDuni0BAA_uni0BC1 இuni0BA9_uni0BCDேஹலH 
அuni0BB2_uni0BCDலuni0BA4_uni0BC1 nebulizer மuni0BB0_uni0BC1uni0BA8_uni0BCDuni0BA4_uni0BC1 (அதாவuni0BA4_uni0BC1 ெசேராuni0BAA_uni0BCDேலா  அuni0BB8_uni0BCDதலிuni0BA9_uni0BCD 
ேபாuni0BA9_uni0BCDற) எuni0BA4_uni0BCDதைன uni0BAE_uni0BC1ைற பயuni0BA9_uni0BCDபuni0B9F_uni0BC1uni0BA4_uni0BCDதின $ Hகuni0BB3_uni0BCD? 
1. ஒuni0BB0_uni0BC1 நாைளuni0B95_uni0BCDuni0B95_uni0BC1 3 அuni0BB2_uni0BCDலuni0BA4_uni0BC1 அதuni0BB1_uni0BCDuni0B95_uni0BC1 ேமuni0BB1_uni0BCDபuni0B9F_uni0BCDட uni0BAE_uni0BC1ைற 
2. நாெளாuni0BA9_uni0BCDuni0BB1_uni0BC1uni0B95_uni0BCDuni0B95_uni0BC1 1 அuni0BB2_uni0BCDலuni0BA4_uni0BC1 2 uni0BAE_uni0BC1ைற 
3. வாரuni0BA4_uni0BCDதிuni0BB1_uni0BCDuni0B95_uni0BC1 2 அuni0BB2_uni0BCDலuni0BA4_uni0BC1 3 uni0BAE_uni0BC1ைற  
4. வாரuni0BA4_uni0BCDதிuni0BB1_uni0BCDuni0B95_uni0BC1 1 uni0BAE_uni0BC1ைற 
5. uni0BAE_uni0BC1uni0BB1_uni0BCDறிuni0BB2_uni0BC1uni0BAE_uni0BCD  இuni0BB2_uni0BCDைல 
 
5. கடuni0BA8_uni0BCDத 4 வாரuni0B99_uni0BCDகளிuni0BA9_uni0BCD ேபாuni0BA4_uni0BC1   
உuni0B99_uni0BCDகuni0BB3_uni0BCD   ஆuni0BB8_uni0BCDuni0BA4_uni0BCDமாவிuni0BA9_uni0BCD  கuni0B9F_uni0BCDuni0B9F_uni0BC1பாuni0B9F_uni0BCDைட ந$uni0B99_uni0BCDகuni0BB3_uni0BCD  எuni0BAA_uni0BCDபuni0B9F_uni0BBF 
மதிuni0BAA_uni0BCDபிuni0B9F_uni0BC1வ $Hகuni0BB3_uni0BCD ? 
1. uni0BAE_uni0BC1uni0BB1_uni0BCDறிuni0BB2_uni0BC1uni0BAE_uni0BCD கuni0B9F_uni0BCDuni0B9F_uni0BC1uni0BAA_uni0BCDபாuni0B9F_uni0BCDuni0B9F_uni0BBFuni0BB2_uni0BCD  இuni0BB2_uni0BCDைல 
2. ேமாசமான கuni0B9F_uni0BCDuni0B9F_uni0BC1uni0BAA_uni0BCDபாuni0B9F_uni0BC1  
3. ஓரளuni0BB5_uni0BC1 கuni0B9F_uni0BCDuni0B9F_uni0BC1uni0BAA_uni0BCDபாuni0B9F_uni0BC1  
4. நuni0BA9_uni0BCDuni0B95_uni0BC1 கuni0B9F_uni0BCDuni0B9F_uni0BC1uni0BAA_uni0BCDபாuni0B9F_uni0BC1  
5. uni0BAE_uni0BC1uni0BB4_uni0BC1ைமயான கuni0B9F_uni0BCDuni0B9F_uni0BC1uni0BAA_uni0BCDபாuni0B9F_uni0BC1       Total score :                                
  
xg;Gjy; gbtk; 
,uh. fPh;j;jdh gpuhl;bah Mfpa ehd; PSG kUj;Jtf; fy;Yhupapd;  Pharmacology Jiwapd; fPo;> GRK 
5 ghypkhh;gp]k; kw;Wk; Nkhrkhf fl;Lg;gLj;jg;gl;l M];Jkh ,ilNa cs;s njhlh;G vd;w jiyg;gpy; Ma;T 
Nkw;nfhs;s cs;Nsd;.  
vd; Ma;T topfhl;b:  Nguhrpupah;. R. ,uhkypq;fk;  
Ma;T Nkw;nfhs;tjw;fhd mbg;gil: GRK 5 vd;w kugZtpdhy; M];Jkhtpd; fl;Lg;ghL Fiwfpwjh 
vd;gij mwpa  
Ma;tpd; Nehf;fk;: kugZtpd; khw;wj;jpw;Fk; M];Jkhtpd; fl;Lg;ghl;bw;Fk; cs;s njhlh;G  
Ma;T Nkw;nfhs;Sk; ,lk;:     PSG kUj;Jt fy;Yhhp kUj;Jtkid  
Ma;T gyd;fs;:   tUk; fhyq;fspd; vd; Ma;tpdhy; rpwe;j Kiwapy; M];Jkhit fl;Lg;gLj;j ,aYk; 
,e;j Ma;tpy; fpilf;Fk; jfty;fs; 5 tUlq;fs; ghJfhf;fg;gLk;. ,it NtW ve;j Ma;tpw;Fk; gad;gLj;jg; gl 
khl;lhJ. ve;j epiyapYk; cq;fisg; gw;wpa jfty;fs; ahUf;Fk; njhptpf;fg;gl khl;lhJ. mit ,ufrpakhf 
itf;fg;gLk;.  
,e;j Ma;tpy; gq;Nfw;f xg;Gf;nfhs;Stjhy; ve;j tpjkhd gyDk; cq;fSf;F fpilf;fhJ. ve;j Neuj;jpy; 
Ntz;LkhdhYk; Ma;tpypUe;J tpyfpf;nfhs;Sk; cupik cq;fSf;F cz;L. Ma;tpypUe;J tpyfpf;nfhs;tjhy; 
cq;fSf;F mspf;fg;gLk; rpfpr;irapy; ve;j tpj khw;wKk; ,Uf;fhJ.  
,e;j Muha;r;rpf;fhf cq;fsplk; rpy Nfs;tpfs; Nfl;fg;gLk;. 2ml ,uj;j khjpupfs; vLf;fg;gLk;.  
NkYk;> ,e;j Ma;tpy; gq;F nfhs;tJ cq;fs; nrhe;j tpUg;gk;. ,jpy; ve;j tpjf; fl;lhaKk; ,y;iy. ePq;fs; 
tpUg;gg; gl;lhy;> ,e;j Ma;tpd; KbTfs;  cq;fSf;Fj; njhpag;gLj;jg;gLk;.  
Ma;thshpd; ifnahg;gk; /Njjp       : 
Ma;Tf;Fl;gLgthpd; xg;Gjy; :  
ehd; ,e;j Muha;r;rpapd; Nehf;fk; kw;Wk; mjd; gad;ghl;bidg; gw;wp njspthfTk;> tpsf;fkhfTk; 
njhpag;gLj;jg; gl;Ls;Nsd;. ,e;j Muha;r;rpapy; gq;F nfhs;sTk;. ,e;j Muha;r;rpapd; kUj;Jt uPjpahd 
Fwpg;Gfis tUk; fhyj;jpYk; cgNahfg;gLj;jpf; nfhs;sTk; KO kdJld; rk;kjpf;fpNwd;.  
 
Ma;Tf;Fl;gLgthpd;  ngah;> Kfthp   :           
 ifnahg;gk; & Njjp             
 
MASTER CHART 
ID NO AGE SEX CONTROL SNP 
BAS 1 21 F P WILD HOMO 
BAS 2 44 F P WILD HOMO 
BAS 3 37 F W WILD HOMO 
BAS 4 21 M W WILD HOMO 
BAS 5 67 F W WILD HOMO 
BAS 6 56 F W WILD HOMO 
BAS 7 52 M W HETERO 
BAS 8 32 F P WILD HOMO 
BAS 9 65 F W WILD HOMO 
BAS 10 31 F W HETERO 
BAS 11 21 M P WILD HOMO 
BAS 12 39 M P WILD HOMO 
BAS 13 42 F P WILD HOMO 
BAS 14 51 F W WILD HOMO 
BAS 15 34 M P WILD HOMO 
BAS 16 69 M W HETERO 
BAS 17 54 F P WILD HOMO 
BAS 18 69 F W WILD HOMO 
BAS 19 33 F W WILD HOMO 
BAS 20 77 F P WILD HOMO 
BAS 21 47 M W WILD HOMO 
BAS 22 60 F W WILD HOMO 
BAS 23 52 F P WILD HOMO 
BAS 24 35 M W WILD HOMO 
BAS 25 54 F P WILD HOMO 
BAS 26 70 F P WILD HOMO 
BAS 27 76 F P WILD HOMO 
BAS 28 58 M P WILD HOMO 
BAS 29 71 M W WILD HOMO 
BAS 30 40 F W WILD HOMO 
BAS 31 47 M W WILD HOMO 
BAS 32 65 F W WILD HOMO 
BAS 33 40 F W WILD HOMO 
BAS 34 24 M P WILD HOMO 
BAS 35 23 F P WILD HOMO 
BAS 36 49 M P WILD HOMO 
BAS 37 61 F W WILD HOMO 
BAS 38 57 F P WILD HOMO 
BAS 39 64 M W WILD HOMO 
BAS 40 20 F W WILD HOMO 
BAS 41 35 F W HETERO 
MASTER CHART 
BAS 42 32 M W WILD HOMO 
BAS 43 24 F W WILD HOMO 
BAS 44 43 F W WILD HOMO 
BAS 45 57 M W WILD HOMO 
BAS 46 36 F P WILD HOMO 
BAS 47 55 F P WILD HOMO 
BAS 48 45 F W WILD HOMO 
BAS 49 80 F P WILD HOMO 
BAS 50 23 F W WILD HOMO 
BAS 51 32 F W HETERO 
BAS 52 40 M W WILD HOMO 
BAS 53 55 F P WILD HOMO 
BAS 54 32 F W WILD HOMO 
BAS 55 35 F W HETERO 
BAS 56 63 M P WILD HOMO 
BAS 57 49 F W WILD HOMO 
BAS 58 31 F W WILD HOMO 
BAS 59 42 M W HETERO 
BAS 60 72 M W WILD HOMO 
BAS 61 55 F W WILD HOMO 
BAS 62 30 F P WILD HOMO 
BAS 63 50 F W HETERO 
BAS 64 52 F W WILD HOMO 
BAS 65 60 F W WILD HOMO 
BAS 66 53 F W WILD HOMO 
BAS 67 38 F W WILD HOMO 
BAS 68 41 F W WILD HOMO 
BAS 69 32 F W WILD HOMO 
BAS 70 27 M W WILD HOMO 
BAS 71 63 F P WILD HOMO 
BAS 72 72 M W WILD HOMO 
BAS 73 47 F W HETERO 
BAS 74 43 F P WILD HOMO 
BAS 75 35 F W HETERO 
BAS 76 60 F P WILD HOMO 
BAS 77 55 F W WILD HOMO 
BAS 78 65 M W WILD HOMO 
BAS 79 52 F W WILD HOMO 
BAS 80 36 F W WILD HOMO 
BAS 81 43 M W WILD HOMO 
BAS 82 39 M W WILD HOMO 
BAS 83 26 M P WILD HOMO 
MASTER CHART 
BAS 84 48 F W HETERO 
BAS 85 26 F W WILD HOMO 
BAS 86 42 F W WILD HOMO 
BAS 87 26 F W WILD HOMO 
BAS 88 28 F W WILD HOMO 
BAS 89 49 F W WILD HOMO 
BAS 90 60 F P WILD HOMO 
BAS 91 60 F W WILD HOMO 
BAS 92 29 F P WILD HOMO 
BAS 93 57 F W WILD HOMO 
BAS 94 67 M P WILD HOMO 
BAS 95 25 M W WILD HOMO 
BAS 96 59 F W WILD HOMO 
BAS 97 39 M P WILD HOMO 
BAS 98 48 F W WILD HOMO 
BAS 99 21 M W WILD HOMO 
BAS 100 47 M P WILD HOMO 
BAS 101 65 F W WILD HOMO 
BAS 102 24 F W WILD HOMO 
BAS 103 28 F W WILD HOMO 
BAS 104 69 F W WILD HOMO 
BAS 105 52 M P WILD HOMO 
BAS 106 42 M P WILD 
MUTANT 
BAS 107 83 M P HETERO 
BAS 108 63 M W WILD HOMO 
BAS 109 52 F P WILD HOMO 
BAS 110 36 F W WILD HOMO 
BAS 111 64 M W HETERO 
BAS 112 65 F P WILD HOMO 
BAS 113 64 M W WILD HOMO 
BAS 114 42 F W WILD HOMO 
BAS 115 80 F W WILD HOMO 
BAS 116 65 F W WILD HOMO 
BAS 117 46 F W WILD HOMO 
BAS 118 26 F P WILD HOMO 
BAS 119 50 M P WILD HOMO 
BAS 120 50 M W WILD HOMO 
BAS 121 34 M P WILD HOMO 
BAS 122 50 F P WILD HOMO 
BAS 123 49 F P WILD HOMO 
BAS 124 74 F P WILD HOMO 
MASTER CHART 
BAS 125 47 M P WILD HOMO 
BAS 126 32 M P HETERO 
BAS 127 62 F P WILD HOMO 
BAS 128 42 F P HETERO 
BAS 129 63 F P WILD HOMO 
BAS 130 52 F P HETERO 
BAS 131 55 F P WILD HOMO 
BAS 132 65 M P HETERO 
BAS 133 59 M P WILD HOMO 
BAS 134 37 F P WILD HOMO 
BAS 135 45 M P WILD HOMO 
BAS 136 58 F P HETERO 
BAS 137 19 M P WILD HOMO 
BAS 138 32 M P WILD HOMO 
BAS 139 71 M P WILD HOMO 
BAS 140 69 F P HETERO 
BAS 141 22 F P HETERO 
BAS 142 45 F P WILD HOMO 
BAS 143 59 F P WILD HOMO 
BAS 144 71 F P WILD HOMO 
BAS 145 35 F P WILD HOMO 
BAS 146 50 F P WILD HOMO 
BAS 147 65 F P WILD HOMO 
BAS 148 22 F P WILD HOMO 
BAS 149 63 F P HETERO 
BAS 150 21 M P WILD HOMO 
BAS 151 53 F P WILD HOMO 
BAS 152 43 F P WILD HOMO 
BAS 153 26 F P WILD HOMO 
BAS 154 29 M P WILD HOMO 
BAS 155 69 F P HETERO 
BAS 156 31 F P WILD HOMO 
BAS 157 77 M P WILD HOMO 
BAS 158 33 F P WILD HOMO 
BAS 159 46 F P WILD HOMO 
BAS 160 63 F P WILD HOMO 
 
